Ovid Therapeutics Inc. rose 4.29% in premarket trading, with the company announcing its participation in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. This event provides a platform for the company to showcase its advancements in developing small molecule medicines for brain conditions with significant unmet needs, which is likely driving investor optimism.
Comments
No comments yet